ID   KCIP2_RAT               Reviewed;         270 AA.
AC   Q9JM59; Q9JI21; Q9JI22; Q9JI23; Q9JM60;
DT   16-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   16-AUG-2005, sequence version 2.
DT   24-JUL-2024, entry version 156.
DE   RecName: Full=A-type potassium channel modulatory protein KCNIP2 {ECO:0000305};
DE   AltName: Full=Kv channel-interacting protein 2;
DE            Short=KChIP2 {ECO:0000303|PubMed:16820361};
DE   AltName: Full=Potassium channel-interacting protein 2;
GN   Name=Kcnip2 {ECO:0000312|RGD:70887};
GN   Synonyms=Kchip2 {ECO:0000303|PubMed:16820361};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), INTERACTION WITH KCND3,
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Brain;
RX   PubMed=11263977; DOI=10.1006/bbrc.2001.4558;
RA   Ohya S., Morohashi Y., Muraki K., Tomita T., Watanabe M., Iwatsubo T.,
RA   Imaizumi Y.;
RT   "Molecular cloning and expression of the novel splice variants of K(+)
RT   channel-interacting protein 2.";
RL   Biochem. Biophys. Res. Commun. 282:96-102(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, PALMITOYLATION AT CYS-45 AND CYS-46, AND MUTAGENESIS OF
RP   45-CYS-CYS-46.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=12006572; DOI=10.1074/jbc.m203651200;
RA   Takimoto K., Yang E.-K., Conforti L.;
RT   "Palmitoylation of KChIP splicing variants is required for efficient cell
RT   surface expression of Kv4.3 channels.";
RL   J. Biol. Chem. 277:26904-26911(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Heart;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, INTERACTION WITH KCND2 AND KCND3, AND TISSUE SPECIFICITY.
RX   PubMed=10676964; DOI=10.1038/35000592;
RA   An W.F., Bowlby M.R., Betty M., Cao J., Ling H.-P., Mendoza G.,
RA   Hinson J.W., Mattsson K.I., Strassle B.W., Trimmer J.S., Rhodes K.J.;
RT   "Modulation of A-type potassium channels by a family of calcium sensors.";
RL   Nature 403:553-556(2000).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=12646414; DOI=10.1152/ajpcell.00416.2002;
RA   Boland L.M., Jiang M., Lee S.Y., Fahrenkrug S.C., Harnett M.T.,
RA   O'Grady S.M.;
RT   "Functional properties of a brain-specific NH2-terminally spliced modulator
RT   of Kv4 channels.";
RL   Am. J. Physiol. 285:C161-C170(2003).
RN   [6]
RP   FUNCTION, INTERACTION WITH KCND2, AND SUBCELLULAR LOCATION.
RX   PubMed=16820361; DOI=10.1074/jbc.m604843200;
RA   Han W., Nattel S., Noguchi T., Shrier A.;
RT   "C-terminal domain of Kv4.2 and associated KChIP2 interactions regulate
RT   functional expression and gating of Kv4.2.";
RL   J. Biol. Chem. 281:27134-27144(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24793047; DOI=10.1007/s00424-014-1521-3;
RA   Rudakova E., Wagner M., Frank M., Volk T.;
RT   "Localization of Kv4.2 and KChIP2 in lipid rafts and modulation of outward
RT   K(+) currents by membrane cholesterol content in rat left ventricular
RT   myocytes.";
RL   Pflugers Arch. 467:299-309(2015).
CC   -!- FUNCTION: Regulatory subunit of Kv4/D (Shal)-type voltage-gated rapidly
CC       inactivating A-type potassium channels (PubMed:10676964,
CC       PubMed:16820361). Modulates channel density, inactivation kinetics and
CC       rate of recovery from inactivation in a calcium-dependent and isoform-
CC       specific manner (PubMed:10676964, PubMed:16820361). Involved in KCND2
CC       and KCND3 trafficking to the cell surface (By similarity). Essential
CC       for the expression of I(To) currents in the heart (By similarity).
CC       Required for normal protein levels of KCND2 in the heart ventricle (By
CC       similarity). {ECO:0000250|UniProtKB:Q9JJ69,
CC       ECO:0000250|UniProtKB:Q9NS61, ECO:0000269|PubMed:10676964,
CC       ECO:0000269|PubMed:16820361}.
CC   -!- SUBUNIT: Component of heteromultimeric potassium channels. Identified
CC       in potassium channel complexes containing KCND1, KCND2, KCND3, KCNIP1,
CC       KCNIP2, KCNIP3, KCNIP4, DPP6 and DPP10 (By similarity). The KCND2-
CC       KCNIP2 channel complex contains four KCND2 and four KCNIP2 subunits (By
CC       similarity). Interacts with KCND2 (PubMed:16820361). Probably part of a
CC       complex consisting of KCNIP1, KCNIP2 isoform 3 and KCND2. At least
CC       isoform 2 and isoform 3 can self-associate to form homodimers and
CC       homotetramers. Isoform 3 interacts with KCNIP1 in a calcium-dependent
CC       manner (By similarity). Interacts with KCND3; each KCNIP2 monomer
CC       interacts with two adjacent KCND3 subunits, through both the N-terminal
CC       inactivation ball of a KCND3 subunit and a C-terminal helix from the
CC       adjacent KCND3 subunit, clamping them together; this interaction
CC       modulates the channel gating kinetics (PubMed:10676964,
CC       PubMed:11263977). {ECO:0000250|UniProtKB:Q9JJ69,
CC       ECO:0000250|UniProtKB:Q9NS61, ECO:0000269|PubMed:10676964,
CC       ECO:0000269|PubMed:11263977, ECO:0000269|PubMed:16820361}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11263977,
CC       ECO:0000269|PubMed:12006572, ECO:0000269|PubMed:16820361,
CC       ECO:0000269|PubMed:24793047}; Lipid-anchor
CC       {ECO:0000269|PubMed:12006572}. Note=Detected on lipid rafts.
CC       {ECO:0000269|PubMed:24793047}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=B, KCHIP2a, KChIP2L, rKCHIP2b;
CC         IsoId=Q9JM59-1; Sequence=Displayed;
CC       Name=2; Synonyms=KCHIP2b;
CC         IsoId=Q9JM59-2; Sequence=VSP_015065;
CC       Name=3; Synonyms=rKCHIP2a, KCHIP2L;
CC         IsoId=Q9JM59-3; Sequence=VSP_015064;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, brain and lung. In brain,
CC       abundantly expressed in striatum, hippocampus and olfactory bulb,
CC       moderately expressed in cerebral cortex and lowly expressed in thalamus
CC       and hypothalamus. Isoform 1 is predominant in cerebral cortex, striatum
CC       and hippocampus. Isoform 1, isoform 2 and isoform 3 are equally
CC       expressed in olfactory bulb. Iisoform 3 is expressed at high levels and
CC       isoform 1 at low levels in heart (in PubMed:11263977).
CC       {ECO:0000269|PubMed:10676964, ECO:0000269|PubMed:11263977,
CC       ECO:0000269|PubMed:12006572, ECO:0000269|PubMed:12646414}.
CC   -!- PTM: Palmitoylated. Palmitoylation enhances association with the plasma
CC       membrane. {ECO:0000269|PubMed:12006572}.
CC   -!- SIMILARITY: Belongs to the recoverin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB040031; BAA92743.1; -; mRNA.
DR   EMBL; AB040032; BAA92744.1; -; mRNA.
DR   EMBL; AF269283; AAF81755.1; -; mRNA.
DR   EMBL; AF269284; AAF81756.1; -; mRNA.
DR   EMBL; AF269285; AAF81757.1; -; mRNA.
DR   EMBL; BC085905; AAH85905.1; -; mRNA.
DR   PIR; JC7631; JC7631.
DR   RefSeq; NP_001029133.1; NM_001033961.1. [Q9JM59-3]
DR   RefSeq; NP_064479.2; NM_020094.2. [Q9JM59-1]
DR   RefSeq; NP_064480.2; NM_020095.2. [Q9JM59-2]
DR   RefSeq; XP_008758701.1; XM_008760479.2.
DR   RefSeq; XP_008758702.1; XM_008760480.2.
DR   RefSeq; XP_008758704.1; XM_008760482.2.
DR   RefSeq; XP_017445315.1; XM_017589826.1.
DR   RefSeq; XP_017445321.1; XM_017589832.1.
DR   RefSeq; XP_017445328.1; XM_017589839.1.
DR   AlphaFoldDB; Q9JM59; -.
DR   SMR; Q9JM59; -.
DR   BioGRID; 248591; 2.
DR   CORUM; Q9JM59; -.
DR   STRING; 10116.ENSRNOP00000040277; -.
DR   iPTMnet; Q9JM59; -.
DR   PhosphoSitePlus; Q9JM59; -.
DR   SwissPalm; Q9JM59; -.
DR   PaxDb; 10116-ENSRNOP00000059337; -.
DR   ABCD; Q9JM59; 2 sequenced antibodies.
DR   Ensembl; ENSRNOT00000024709.6; ENSRNOP00000024709.4; ENSRNOG00000018018.9. [Q9JM59-1]
DR   Ensembl; ENSRNOT00000024750.5; ENSRNOP00000024750.3; ENSRNOG00000018018.9. [Q9JM59-3]
DR   Ensembl; ENSRNOT00055007029; ENSRNOP00055005260; ENSRNOG00055004441. [Q9JM59-1]
DR   Ensembl; ENSRNOT00060041813; ENSRNOP00060034671; ENSRNOG00060023989. [Q9JM59-1]
DR   Ensembl; ENSRNOT00065051280; ENSRNOP00065042217; ENSRNOG00065029650. [Q9JM59-1]
DR   GeneID; 56817; -.
DR   KEGG; rno:56817; -.
DR   UCSC; RGD:70887; rat. [Q9JM59-1]
DR   AGR; RGD:70887; -.
DR   CTD; 30819; -.
DR   RGD; 70887; Kcnip2.
DR   VEuPathDB; HostDB:ENSRNOG00000014152; -.
DR   eggNOG; KOG0044; Eukaryota.
DR   GeneTree; ENSGT00940000157798; -.
DR   HOGENOM; CLU_072366_2_2_1; -.
DR   InParanoid; Q9JM59; -.
DR   OrthoDB; 339700at2759; -.
DR   PhylomeDB; Q9JM59; -.
DR   TreeFam; TF318560; -.
DR   Reactome; R-RNO-5576894; Phase 1 - inactivation of fast Na+ channels.
DR   PRO; PR:Q9JM59; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000018018; Expressed in heart and 19 other cell types or tissues.
DR   ExpressionAtlas; Q9JM59; baseline.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0071193; C:Kv4.2-KChIP2 channel complex; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:UniProtKB.
DR   GO; GO:0005250; F:A-type (transient outward) potassium channel activity; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:RGD.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0044325; F:transmembrane transporter binding; ISO:RGD.
DR   GO; GO:0001508; P:action potential; ISO:RGD.
DR   GO; GO:0045163; P:clustering of voltage-gated potassium channels; IDA:RGD.
DR   GO; GO:0086009; P:membrane repolarization; ISO:RGD.
DR   GO; GO:0006936; P:muscle contraction; ISO:RGD.
DR   GO; GO:1903766; P:positive regulation of potassium ion export across plasma membrane; ISO:RGD.
DR   GO; GO:0097623; P:potassium ion export across plasma membrane; ISO:RGD.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; IDA:UniProtKB.
DR   CDD; cd00051; EFh; 2.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR028846; Recoverin.
DR   PANTHER; PTHR23055; CALCIUM BINDING PROTEINS; 1.
DR   PANTHER; PTHR23055:SF65; KV CHANNEL-INTERACTING PROTEIN 2; 1.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   Pfam; PF13833; EF-hand_8; 1.
DR   PRINTS; PR00450; RECOVERIN.
DR   SMART; SM00054; EFh; 3.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   PROSITE; PS00018; EF_HAND_1; 3.
DR   PROSITE; PS50222; EF_HAND_2; 3.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cell membrane; Ion channel; Ion transport;
KW   Lipoprotein; Membrane; Metal-binding; Palmitate; Phosphoprotein; Potassium;
KW   Potassium channel; Potassium transport; Reference proteome; Repeat;
KW   Transport; Voltage-gated channel.
FT   CHAIN           1..270
FT                   /note="A-type potassium channel modulatory protein KCNIP2"
FT                   /id="PRO_0000073824"
FT   DOMAIN          81..137
FT                   /note="EF-hand 1; degenerate"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          140..175
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          176..211
FT                   /note="EF-hand 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          224..259
FT                   /note="EF-hand 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          1..34
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          257..270
FT                   /note="Interaction with KCND2"
FT                   /evidence="ECO:0000250|UniProtKB:Q8R426"
FT   COMPBIAS        1..15
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         153
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         155
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         157
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         159
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         164
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         189
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         191
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         195
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         200
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         237
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         239
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         241
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   MOD_RES         9
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   LIPID           45
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12006572"
FT   LIPID           46
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:12006572"
FT   VAR_SEQ         25..74
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11263977,
FT                   ECO:0000303|PubMed:12006572, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015064"
FT   VAR_SEQ         57..75
FT                   /note="TLAAPASLRPHRPRPLDPD -> N (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12006572"
FT                   /id="VSP_015065"
FT   MUTAGEN         45..46
FT                   /note="CC->AA,SS: Abolishes plasma membrane localization."
FT                   /evidence="ECO:0000269|PubMed:12006572"
FT   CONFLICT        12
FT                   /note="E -> D (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        31
FT                   /note="S -> T (in Ref. 1; BAA92744 and 3; AAH85905)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        50
FT                   /note="A -> V (in Ref. 1; BAA92744 and 3; AAH85905)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        105
FT                   /note="R -> K (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143
FT                   /note="N -> T (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        177
FT                   /note="I -> V (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        182
FT                   /note="S -> N (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        255
FT                   /note="Q -> K (in Ref. 1; BAA92743/BAA92744)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   270 AA;  30933 MW;  C797DEC90FDC3B92 CRC64;
     MRGQGRKESL SESRDLDGSY DQLTGHPPGP SKKALKQRFL KLLPCCGPQA LPSVSETLAA
     PASLRPHRPR PLDPDSVEDE FELSTVCHRP EGLEQLQEQT KFTRRELQVL YRGFKNECPS
     GIVNEENFKQ IYSQFFPQGD SSNYATFLFN AFDTNHDGSV SFEDFVAGLS VILRGTIDDR
     LSWAFNLYDL NKDGCITKEE MLDIMKSIYD MMGKYTYPAL REEAPREHVE SFFQKMDRNK
     DGVVTIEEFI ESCQQDENIM RSMQLFDNVI
//
